INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,031,766 | +189.4% | 702,900 | +93.1% | 0.03% | +125.0% |
| Q4 2022 | $4,503,521 | +1063.7% | 364,068 | +1212.6% | 0.01% | +1100.0% |
| Q3 2022 | $387,000 | +170.6% | 27,736 | +167.2% | 0.00% | – |
| Q2 2022 | $143,000 | -54.6% | 10,380 | -46.3% | 0.00% | -100.0% |
| Q4 2021 | $315,000 | -91.2% | 19,333 | -92.0% | 0.00% | -93.3% |
| Q3 2021 | $3,575,000 | +945.3% | 240,731 | +4326.0% | 0.02% | +275.0% |
| Q1 2020 | $342,000 | -95.4% | 5,439 | -91.0% | 0.00% | -91.1% |
| Q4 2019 | $7,509,000 | -51.0% | 60,595 | -52.3% | 0.04% | -35.7% |
| Q3 2018 | $15,313,000 | +106.1% | 127,000 | +43.4% | 0.07% | +112.1% |
| Q2 2018 | $7,429,000 | +150.7% | 88,534 | +74.6% | 0.03% | +266.7% |
| Q4 2017 | $2,963,000 | -63.9% | 50,716 | -64.1% | 0.01% | -71.9% |
| Q3 2017 | $8,207,000 | -40.4% | 141,400 | +24.4% | 0.03% | -43.9% |
| Q2 2017 | $13,766,000 | +497.0% | 113,704 | +435.7% | 0.06% | +375.0% |
| Q4 2016 | $2,306,000 | -1.4% | 21,227 | +49.5% | 0.01% | -14.3% |
| Q3 2016 | $2,338,000 | – | 14,202 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |